Opinion

Video

Managing Toxicities of Hydroxyurea in Patients With PV

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Idoroenyi Amanam, MD
October 9th 2024

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Kelly Chien, MD
September 22nd 2024

Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs

FDA
September 12th 2024

FDA Grants Orphan Drug Designation to Tebapivat for MDS